1921
Volume 90, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.14-0040a
2014-06-04
2019-05-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/90/6/1191.html?itemId=/content/journals/10.4269/ajtmh.14-0040a&mimeType=html&fmt=ahah

References

  1. Sosa N, Capitan Z, Nieto J, Nieto M, Calzada J, Paz H, Spandafora C, Kreisjman-Deitrick M, Kopydlowski K, Ullman D, McCarthy WF, Ranson J, Berman J, Scott C, Grogl M, , 2013. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg 89: 557563.[Crossref] [Google Scholar]
  2. Krause G, Kroeger A, , 1994. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 88: 9294.[Crossref] [Google Scholar]
  3. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R, , 2004. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for new world cutaneous leishmaniasis. Acta Trop 91: 153160.[Crossref] [Google Scholar]
  4. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Hamida NB, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith SK, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M, , 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524532.[Crossref] [Google Scholar]
  5. ClinicalTrials.gov, Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama. NCT01790659. Available at: http://clinicaltrials.gov/ct2/show/NCT01790659. Accessed January 16, 2014. [Google Scholar]
  6. Blum J, Lockwood DN, Visser L, Harms G, Bailey MS, Caumes E, Clerinx J, van Thiel PP, Morizot G, Hatz C, Buffet P, , 2012. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. In Health 4: 153163.[Crossref] [Google Scholar]
  7. WHO, 2010. Control of the Leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series; no. 949. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed January 16, 2014. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0040a
Loading
  • Published online : 04 Jun 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error